颖泰生物
(920819)
| 流通市值：32.35亿 | | | 总市值：32.73亿 |
| 流通股本：12.12亿 | | | 总股本：12.26亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,901,373,190.99 | 2,763,626,143.04 | 1,355,490,197.14 | 5,474,030,024.74 |
| 营业收入 | 3,901,373,190.99 | 2,763,626,143.04 | 1,355,490,197.14 | 5,474,030,024.74 |
| 二、营业总成本 | 3,906,802,670.8 | 2,736,385,354.36 | 1,364,489,867.01 | 5,533,691,285.33 |
| 营业成本 | 3,352,091,070.41 | 2,371,568,542.72 | 1,193,946,686.53 | 4,779,455,867.49 |
| 税金及附加 | 27,720,327.51 | 17,202,596.58 | 9,594,278.28 | 33,040,783.03 |
| 销售费用 | 66,083,704.82 | 42,900,531.95 | 20,110,579.05 | 92,317,723.24 |
| 管理费用 | 222,549,440.29 | 148,323,554.95 | 67,586,940.44 | 326,790,788.65 |
| 研发费用 | 85,030,277.02 | 51,805,598.75 | 21,101,892.91 | 130,383,752.5 |
| 财务费用 | 153,327,850.75 | 104,584,529.41 | 52,149,489.8 | 171,702,370.42 |
| 其中:利息费用 | 111,450,817.25 | 76,061,864.1 | 37,861,153.25 | 171,796,168.67 |
| 其中:利息收入 | 5,041,007.99 | 3,298,621.97 | 2,365,208.42 | 17,229,582.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -8,019,784.86 | -7,940,809.61 | -3,127,642.63 | -1,370.4 |
| 加:投资收益 | -11,643,039.93 | 30,500,342.49 | 2,265,270.36 | -61,730,501.82 |
| 资产处置收益 | 327,485.27 | 3,608.51 | 2,369,926.58 | 13,433,851.23 |
| 资产减值损失(新) | -20,571,674.88 | -18,513,890.48 | -4,211,815.26 | -95,483,872.25 |
| 信用减值损失(新) | 2,743,036.98 | 2,217,719.32 | 2,709,956.52 | -34,472,398.05 |
| 其他收益 | 13,592,194.7 | 8,732,662.87 | 4,924,766.83 | 29,443,059.13 |
| 四、营业利润 | -29,001,262.53 | 42,240,421.78 | -4,069,207.47 | -208,472,492.75 |
| 加:营业外收入 | 3,051,467.16 | 1,046,124.06 | 2,262,452.12 | 4,040,898.01 |
| 减:营业外支出 | 5,869,007.3 | 2,953,632.55 | 2,190,556.08 | 11,131,214.41 |
| 五、利润总额 | -31,818,802.67 | 40,332,913.29 | -3,997,311.43 | -215,562,809.15 |
| 减:所得税费用 | 42,859,509.38 | 36,433,423.8 | 16,596,706.95 | 44,835,728.95 |
| 六、净利润 | -74,678,312.05 | 3,899,489.49 | -20,594,018.38 | -260,398,538.1 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -74,678,312.05 | 3,899,489.49 | -20,594,018.38 | -260,398,538.1 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -70,526,330.99 | 5,715,241.61 | -19,746,738.88 | -256,943,685.05 |
| 少数股东损益 | -4,151,981.06 | -1,815,752.12 | -847,279.5 | -3,454,853.05 |
| 扣除非经常损益后的净利润 | -71,850,369.73 | 5,020,489.34 | -22,267,965.88 | -282,108,452.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.06 | 0 | -0.02 | -0.21 |
| (二)稀释每股收益 | -0.06 | 0 | -0.02 | -0.21 |
| 八、其他综合收益 | -52,551,036.66 | -36,504,279.67 | -13,752,449.56 | -3,197,989.92 |
| 归属于母公司股东的其他综合收益 | -52,551,036.66 | -36,504,279.67 | -13,752,449.56 | -3,197,989.92 |
| 九、综合收益总额 | -127,229,348.71 | -32,604,790.18 | -34,346,467.94 | -263,596,528.02 |
| 归属于母公司股东的综合收益总额 | -123,077,367.65 | -30,789,038.06 | -33,499,188.44 | -260,141,674.97 |
| 归属于少数股东的综合收益总额 | -4,151,981.06 | -1,815,752.12 | -847,279.5 | -3,454,853.05 |
| 公告日期 | 2026-10-23 | 2026-08-14 | 2026-04-24 | 2026-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |